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InﬂammationSteroid hormones are well-recognized suppressors of the inﬂammatory response, however, their cell- and
tissue-speciﬁc effects in the regulation of inﬂammation are far less understood, particularly for the sex-
related steroids. To determine the contribution of progesterone in the endothelium, we have characterized
and validated an in vitro culture system in which human umbilical vein endothelial cells constitutively
express human progesterone receptor (PR). Using next generation RNA-sequencing, we identiﬁed a selective
group of cytokines that are suppressed by progesterone both under physiological conditions and during path-
ological activation by lipopolysaccharide. In particular, IL-6, IL-8, CXCL2/3, and CXCL1 were found to be direct
targets of PR, as determined by ChIP-sequencing. Regulation of these cytokines by progesterone was also
conﬁrmed by bead-based multiplex cytokine assays and quantitative PCR. These ﬁndings provide a novel
role for PR in the direct regulation of cytokine levels secreted by the endothelium. They also suggest that
progesterone-PR signaling in the endothelium directly impacts leukocyte trafﬁcking in PR-expressing tissues.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Inﬂammation contributes to the susceptibility and progression of
many diseases that exhibit gender based differences in prevalence.
These include, but are not limited to, autoimmune disease, cardiovascu-
lar disease and sexually transmitted infections (Kaushic et al., 2011;
McCombe et al., 2009; Meyer et al., 2006). The prevailing hypothesis
is that endocrine–immune interactions drive this sexual dimorphism
by affecting the sensitivity to various inﬂammatory stimuli. Evidence
for this emanates from studies demonstrating the requirement for the
immune system in hormonally controlled processes including implan-
tation, cycling, and pregnancy (Challis et al., 2009; Gilliver, 2010;
Jones, 2004; King and Critchley, 2010; Red-Horse and Drake, 2004;
van Mourik et al., 2009). For example, symptoms of rheumatoid arthri-
tis andmultiple sclerosis are reduced during pregnancy, suggesting that
hormones not only modulate local inﬂammatory reactions, but also can
affect systemic immune responses as well (AdamsWaldorf and Nelson,
2008; Hughes, 2012; Martocchia et al., 2011). While much is known ofolysaccharide; HUVEC, human
ceptor knockout; hPR, human
dole.
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rispe).
nc. Open access under CC BY-NC-ND lthe cellular and molecular control of the immune system by estrogen,
glucocorticoids, and androgen signaling, the action of progesterone
and its downstream targets are far less understood.
Progesterone has been generally assumed to play an anti-
inﬂammatory role in immune regulation. In fact, the physiological
reduction of progesterone prior to menstruation and preceding labor
results in a marked inﬂux of inﬂammatory cells (macrophages, neutro-
phils, and T cells) into the decidua resembling a local inﬂammatory re-
sponse (Hamilton et al., 2012, 2013; Jones, 2004; Shynlova et al., 2008).
Moreover, mice with complete deletion of PR (PRKO) were found to
have increased immune cell inﬁltration into the uterus and impaired
thymic function (Tibbetts et al., 1999a, 1999b). At the cellular level, PR
expression has been demonstrated in a variety of immune cell types
indicative of a direct regulation by progesterone (Butts et al., 2008;
Gilliver, 2010; Hughes, 2012). However, these ﬁndings do not explain
progesterone control of other leukocyte populations that do not express
PR in vivo, such as natural killer cells and granulocytes. Therefore, it is
likely that paracrine factors such as cytokines and chemokines act as
effectors of steroid hormones, thus enabling systemic immunemodula-
tion in the absence of leukocyte steroid receptors. In fact, there is ample
evidence in the literature for regulation of immune function by proges-
terone through its effect on smooth muscle, stromal, and perivascular
cells (Gotkin et al., 2006; Hardy et al., 2006; Luk et al., 2010; Shields et
al., 2005; Shynlova et al., 2008). Due to its multiple cellular targets, a
comprehensive dissection of cell speciﬁc signaling, as well as direct
downstream targets of PR, is necessary to understand the multiple
immune-modulatory functions of progesterone.icense.
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and is an important barrier in the regulation of leukocyte extravasa-
tion into tissues (Ley et al., 2007; Pober and Sessa, 2007). Upon acti-
vation by an inﬂammatory stimulus, endothelial cells acquire new
capabilities including cytokines/chemokine secretion and the expres-
sion of endothelial–leukocyte adhesion molecules (Pober and Sessa,
2007). Several reports have demonstrated expression of PR within
different human vascular beds (Ingegno et al., 1988; Iruela-Arispe
et al., 1999; Krikun et al., 2005; Maybin and Duncan, 2004; Perrot-
Applanat et al., 1995; Rodríguez-Manzaneque et al., 2000), including
endothelial cells of human atherosclerotic vessels (Vázquez et al.,
1999). Functionally, progesterone has been found to mediate endo-
thelial cell proliferation, transcriptional repression of endothelial–
leukocyte adhesion molecules, as well as MMP secretion (Otsuki et
al., 2001; Rodríguez-Manzaneque et al., 2000; Vázquez et al., 1999)
implicating a direct function of progesterone in the endothelium.
Therefore, we hypothesized that progesterone signaling may modu-
late the immune system by transcriptionally altering endothelial cell
activation and expression of immunomodulatory factors.
Here we provide evidence that PR signaling in the endothelium
directly regulates cytokine expression both under physiological
conditions, as well as following an acute inﬂammatory stimulus. PR
is able to selectively and directly target a cohort of endothelial cyto-
kines resulting in transcriptional repression and reduction in protein
levels by the endothelium. These ﬁndings expand our understanding
of the cell speciﬁc function of progesterone in the endothelium and its
potential role in immune regulation through direct mediation of
cytokine production.
2. Materials and methods
2.1. Virus production and transduction
Human PR cDNA was PCR ampliﬁed and cloned into a lentiviral
vector using the following primers with attached restriction site
sequences: 5′-PR-Xbal (GCTATCTAGAATGACTGAGCTGAAGGCA) and 3′-
PR-STOP-EcoRI (GCTAGAATTCCTACTTTTTATGAAAGAGAAG). Lentivirus-
based vectors encoding PR cDNA were generated by transient
cotransfection of 293 T cells with a three-plasmid combination, as
described previously, with slight modiﬁcations (Naldini et al., 1996).
The construct pMD.G was used for the production of the VSV-G viral
envelope in combination with the packaging constructs pMDLg/pRRE
and pRSV-REV, whereas the pRRL constructions correspond to the
different transfer vectors. Brieﬂy, 100 mm dishes of nonconﬂuent
293 T cells were co-transfected with 6.5 μg of pMDLg/pRRE, 3.5 μg of
pMDG (encoding the VSV-G envelope), 2.5 μg of pRSV-REV and 10 μg
of pRRL-hPR, by the CaPi-DNA coprecipitation method (Chen and
Okayama, 1987; Sakoda et al., 1992). The plasmid vectors were provid-
ed by Dr Luigi Naldini (University of Torino, Italy). Next day, the medi-
um was adjusted to make a ﬁnal concentration of 10 mM sodium
butyrate and the cells were incubated for 8 h to obtain high-titer virus
production as previously described (Sakoda et al., 1999). Conditioned
medium was harvested 16 h later and passed through 0.45 mm ﬁlters.
Viral titer was determined by assessing viral p24 antigen concentration
by ELISA (theAlliance®HIV-I p24 ELISAKit, Perkin Elmer) andhereafter
expressed as μg of p24 equivalent units per milliliter.
2.2. Cell culture
Human umbilical vein endothelial cells were cultured in MCDB-
131 media (VEC Technologies, Rensselaer, NY) supplemented with
charcoal stripped fetal bovine serum (Omega Scientiﬁc, Tarzana,
CA). For bead-based multiplex cytokine arrays, HUVECs were grown
to conﬂuence in 48 well plates and treated with LPS (1 μM; 0111:
B4; Sigma, St. Louis, MO) and/or progesterone (100 nM; Sigma, St.
Louis, MO) for 4, 8, and 24 h. Media without serum were collected,and run in triplicate on a 42-plex array analyzed by Eve Technologies.
For immunocytochemistry, HUVECs were seeded onto Lab-Tek II
8-well chamber slides (Thermo Scientiﬁc, Rochester, NY) and ﬁxed
with 4% paraformaldehyde. Cells were probed with an antibody
against PR (1:400; clone SP2, Lab Vision, Kalamazoo, MI) followed
by an Alexa Fluor secondary (1:300, Invitrogen, Grand Island, NY).
Nuclei were stained using 4′,6-diamidino-2-phenylindole (DAPI,
1:1000; Invitrogen, Grand Island, NY). Images were acquired using a
Zeiss LSM 520 multiphoton microscope (Zeiss, Germany).
2.3. Immunoblotting
Total HUVEC lysates were resolved by SDS-PAGE, and nitrocellu-
lose membranes (Optitran BA-S 83; Dassel, Germany) were incubated
overnight with an anti-PR antibody (1:2000; clone SP2, Lab Vision,
Kalamazoo, MI) and anti-GAPDH antibody (1:1000, Millipore, Billerica,
MA). Blots were incubated with HRP-conjugated secondary (1:5000;
Bio-Rad Laboratories, Hercules, CA) and developed using Supersignal
West Pico Chemiluminescent Substrate (Thermo Scientiﬁc, Kalamazoo,
MI). A Bio-Rad ChemiDoc XRS+ and accompanying Image Lab software
was used for detection (Bio-Rad Laboratories, Hercules, CA).
2.4. RNA isolation, qPCR, and library preparation
Total RNA was extracted using RNeasy Kit (Qiagen, Valencia, CA).
RNA was reverse transcribed using SuperScript First-strand Synthesis
System (Invitrogen, Grand Island, NY). qPCR was performed using
SYBR Green reagent (Qiagen, Valencia, CA) and PCR products were
run on an Opticon2 PCR machine (MJ Research; BioRad, Hercules,
CA). Libraries for RNA-sequencing were generated using an Illumina
Multiplex System (Illumina, San Diego, CA) and sequenced using
HIseq-2000 (Illumina, San Diego, CA). RNA-seq datasets have been
deposited in the NCBI Gene Expression Omnibus with the accession
number GSE46502.
2.5. RNA-seq analysis
Multiplex runs were debarcoded by in house Unix shell script.
Reads were aligned to the human genome (hg19) using TopHat
v2.0.4 (Trapnell et al., 2009) and processed with Cufﬂinks v2.0.1
(Trapnell et al., 2010). Assemblies for all samples were merged
using CuffMerge and pairwise differential expression was assessed
using Cuffdiff. Genes with a p-value smaller than 0.01 where consid-
ered signiﬁcant. Heatmaps with relative expression were generated
by visualizing the log2 values of each gene rpkm divided with the av-
erage rpkm of all samples using Java treeview (de Hoon et al., 2004).
2.6. ChIP-sequencing and analysis
HUVECs were infected with hPR lentivirus, grown to conﬂuence,
and treated with progesterone for 1 h. For each condition (non-
infected-negative control, PR + P, PR only, and IgG control)
10 × 106 cultured HUVECs were used per IP. Cells were crosslinked
with 1% formaldehyde, resuspended in 400 μL of lysis buffer (1%
SDS, 20 mM EDTA and 50 mM Tris–HCl (pH 8.0)) containing prote-
ase inhibitors (Roche, Indianapolis, IN), and sonicated to achieve
200 bp fragments. Samples were immunoprecipitated with 3 μg of
anti-PR or IgG antibody. Protein A Dynabeads (Invitrogen, Grand
Island, NY) were used to isolate antibody–PR complexes and eluted
using 50 mM Tris–HCl, pH 8.0. Crosslinks were reversed by incuba-
tion at 65 °C and DNA was puriﬁed using Qiagen MinElute Columns.
Libraries were generated using Ovation Ultralow IL Multiplex System
1–8 (Nugen, San Carlos, CA) and sequenced using HIseq-2000
(Illumina, San Diego, CA). ChIP-seq data sets have been deposited in
the NCBI Gene Expression Omnibus with the accession number
GSE43786.
Fig. 1. Generation of a lentivirus for human PR expression. (A) Histological sections
demonstrate PR expression in the endothelium of veins (V) but not arteries (A) inmurine
uterine vasculature. PRKO tissue was used as a negative control. Arrows indicate PR pos-
itive endothelial cells. L = lymphatics Scale = 25 μm. (B) Scheme depicting human PR
(hPR) and GFP control lentiviral constructs. PR cDNA was cloned directly following a
CMVpromoter. eGFP and puromycin resistancewere used to determine infection efﬁcien-
cy and confer selection, respectively. (C) Human umbilical vein endothelial cells infected
with aGFP-control or hPR lentivirus. GFP (green) andphase imageswere superimposed to
determine infection efﬁciency. Scale bar = 50 μm. (D) Conﬁrmation that GFP expression
(green) correlates with PR expression (red). DAPI (blue) marks cell nuclei. Scale bar =
20 μm. (E) Western blot analysis of total protein levels from GFP control or hPR infected
HUVECs at various viral concentrations. GAPDH was used as a loading control. In all
panels, results are representative of 3–5 independent experiments.
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hannonlab.cshl.edu/fastx_toolkit) and reads were mapped to the
human genome (hg19) using bowtie v0.12.7 (Langmead et al., 2009).
12–22 million uniquely mapped reads were obtained for each sample.
Peak identiﬁcation was performed with MACS v1.3.7.1 (Zhang et al.,
2008). Peaks were called by comparing peaks in PR and PR + P condi-
tions to that of the input, negative control (non-infected cells) or IgG
control. Only peaks that appeared in all three comparisons were
determined to be noteworthy. Genes potentially regulated by PR were
determined by mapping peaks to nearby genes within 200 kb of the
transcriptional start site using the Genomic Regions Enrichment of
Annotations Tool (McLean et al., 2010). Intersection of PR binding
associated genes with differentially expressed genes was performed
using Unix shell scripts.
2.7. Statistical analysis
All data were analyzed using a Student unpaired two-tailed t-test.
p-Values less than 0.05 were considered to be statistically signiﬁcant.
3. Results
3.1. Generation and validation of a lentivirus for expression of human PR
A detailed, comprehensive histological examination of PR expres-
sion in the mouse conﬁrmed the presence of PR in the endothelium
(Fig. 1A). Interestingly, PR positive endothelial cells were restricted
to veins, but absent from arteries. Although expressed by different
vascular beds in humans, endothelial PR expression in the mouse
was restricted to the vasculature of the uterus, suggestive of its
unique importance in this organ.
In order to gain a better molecular understanding of progesterone
function in the endothelium, we overexpressed human PR in human
umbilical vein endothelial cells (HUVECs) using lentiviral infection.
Full-length human PR cDNA (hPR) was cloned downstream of a
CMV promoter and preceding sequences for eGFP and puromycin
resistance (Fig. 1B). A lentivirus expressing eGFP under the control
of a CMV promoter was used as a control. HUVECs overexpressing
the GFP or hPR construct looked morphologically normal when com-
pared to uninfected HUVECs (Fig. 1C). PR protein colocalized with
GFP positive cells, conﬁrming GFP as an indicator of PR expressing
cells (Fig. 1D). Western blot analysis demonstrated the expression
of both PR isoforms, PR-A and PR-B, in HUVECs expressing hPR, but
not in cells expressing GFP alone (Fig. 1E). PR protein levels were
most optimally expressed at viral concentrations between 0.16 and
0.13 μg/mL, while higher concentrations led to cell death and reduction
in PR protein expression.
HUVECs expressing hPR were treated with progesterone to evalu-
ate the ability of the transduced receptor to respond to progesterone
(Fig. 2A). Consistent with previous reports, PR was mainly localized to
the nucleus in both the presence and absence of progesterone, but
was almost exclusively localized to the nucleus following progester-
one treatment (Fig. 2A). To determine the optimal infection efﬁciency
of the hPR lentivirus, cells were infected with progressively lower
viral concentrations. Titration of virus demonstrated that concentra-
tions less than 0.16 μg/mL led to a reduction of PR expressing cells
upon quantiﬁcation (Fig. 2B). Therefore, all subsequent experiments
were performed at an hPR lentiviral concentration of 0.16 μg/mL.
3.2. PR negatively regulates endothelial cytokine production
Using next generation RNA sequencing, we explored whether PR
signaling may transcriptionally alter the expression of cytokines by
the endothelium. First, we assessed which cytokines might be spe-
ciﬁcally altered when lipopolysaccharide (LPS) was applied to endo-
thelial cultures for 4 and 8 h. A total of 70 cytokines were included inthe initial analysis. Of these 70, only 27 showed transcript expres-
sion by the endothelium (Fig. 3A), and only 15 of these were signif-
icantly (p b 0.01) altered in the presence of LPS at both 4 and 8 h of
treatment (Fig. 3B). To determine if progesterone altered the ex-
pression of these 15 genes, we examined fold change expression be-
tween HUVECs in the presence of LPS alone and those treated
concurrently with LPS and progesterone (Fig. 3B). Although majori-
ty of these cytokines were downregulated by progesterone, only
ﬁve: including CCL2, IL-6, IL-8, CXCL1 and CXCL2, were considered
to be statistically signiﬁcant (p b 0.01). To assess whether proges-
terone alone, in the absence of LPS, was able to reduce the expres-
sion of these same ﬁve genes, we compared fold change expression
between hPR infected cells in the presence or absence of
progesterone for 4 h (Fig. 3C). Even in the absence of LPS, progester-
one still negatively regulated the expression of IL-8, IL-6, CXCL1, and
CXCL1/2, suggesting that progesterone may modulate cytokine pro-
duction in the absence of an acute inﬂammatory stimulus.
Fig. 2. Validation of hPR responsiveness to progesterone. (A) HUVECs overexpressing hPR were treated with or without progesterone (100 nM) for 1 h. PR (red) localization was
exclusively conﬁned to the nucleus in the presence of progesterone. DAPI (blue) marks cell nuclei. Scale bar = 50 μm. (B) Infection efﬁciency of the hPR lentivirus at several
different viral concentrations. Efﬁciency was determined by dividing PR positive cells (red), by total number of nuclei (DAPI, blue) in 10 independent ﬁelds from three biological
replicates.
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production
To further explore whether PR could directly regulate cytokine ex-
pression, we obtained a global read-out of PR binding sites in the
HUVEC genome using ChIP-sequencing. Activation of the receptor
by progesterone resulted in 9906 PR binding sites. To identify wheth-
er the 5 cytokines signiﬁcantly regulated by progesterone might
be direct targets of PR, it was necessary to combine the ChIP-seq
and RNA-seq datasets. RNA-seq analysis of HUVECs yielded 431
downregulated genes with a p-value less than 0.01. These genes
were then intersected with the list of 3886 genes predicted as
regulated by the PR binding sites obtained from ChIP-seq evaluation.
The analysis revealed 214 genes that were likely directly repressed byFig. 3. PR regulation of cytokine and chemokine expression. (A) Heat map depicting
differential expression of cytokine and chemokines strongly regulated by LPS stimula-
tion of HUVECs for 4 and 8 h compared to nontreated cells. (B) Heat map comparing
differential gene expression between LPS treatment in the presence or absence of pro-
gesterone. Genes included those found to be signiﬁcantly (p b 0.01) upregulated by
LPS treatment as determined from the heat map in panel A. (C) Heat map comparing
differential gene expression between HUVECs treated with or without progesterone.
Genes analyzed were those that were signiﬁcantly (p b 0.01) downregulated by
progesterone in the heat map from panel B. + symbolizes genes that were found to
be directly bound by PR by ChIP-seq analysis.PR. Of this list, 4 out of the 5 cytokines found to be downregulated by
progesterone were also predicted to be direct targets of PR (Fig. 3C).3.4. PR negatively regulates cytokine production by the endothelium
To conﬁrmwhether treatment of the endotheliumwith progester-
one leads to a reduction in cytokine secretion, we performed a
42-multiplex bead-based cytokine array. This approach was set up
to determine whether reduced RNA transcript levels correlated with
cytokine protein production. Of the 42 cytokines analyzed, only 24
were at sufﬁciently high levels to be detected by the array (Table 1).
Analysis of these 24 cytokines uncovered selective regulation of 8
by progesterone, including fractalkine, GRO, IL-6, IL-8, IP-10, MCP-1,
PDGF-AA, and PDGFAB/BB. Cytokine regulation was PR-dependent
as per evaluation of HUVECs transduced with a GFP control construct.
These ﬁndings were very similar to the RNA- and ChIP-seq analyses,
as IL-6, IL-8, CCL2/MCP-1, and CXCL1/GROwere all found to be targets
of PR (Fig. 3C).Table 1
Effect of progesterone on cytokine/chemokine secretion by endothelial cells.a
Cytokine +LPS/P Cytokine +LPS/P
EGF – IL-12(p70) –
Eotaxin – IL-13 –
FGF-2 – IL-15 –
Flt-3 ND IL-17 ND
Fractalkine ↓ IP-10 ↓
G-CSF – MCP-1 ↓
GM-CSF – MCP-3 –
GRO(Pan) ↓ MDC –
INF-alpha2 – MIP-1alpha ND
IL-1beta ND MIP-1beta ND
IL-1ra – PDGF-AA ↓
IL-2 ND PDGFAB/BB ↓
IL-3 ND RANTES –
IL-4 ND CD40L ND
IL-5 ND siL-2Ralpha ND
IL-6 ↓ TGFalpha ND
IL-7 ND TNFbeta ND
IL-8 ↓ VEGFA –
IL-9 ND IFN-gamma ND
IL-10 ND IL-1alpha –
IL-12(p40) – TNFalpha(78) ND
TNFalpha(80) ND
a Samples were run using Multiplexing LASER Bead Technology based on uniquely
colored bead sets able to recognize up to 100 analytes per well. Human 42-plex 96
well plates were used to simultaneously detect 42 different cytokine/chemokines per
sample. Cell culture supernatant from LPS and LPS/P treated HUVECs were run in
duplicate and average concentrations were calculated by comparing the ﬂuorescent
intensity of each analyte to a cytokine/chemokine speciﬁc standard curve (0.64 pg/mL–
10,000 pg/mL). Analyte sensitivities were 0.1 pg/mL–30 pg/mL with most being in the
0.1 pg/mL–1 pg/mL range. ND = non-detectable; – = no change; ↓ = decreased ana-
lyte concentration.
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progesterone treatment
In order to conﬁrm the ﬁndings from the global transcriptome
analysis and the multiplex cytokine array, we more closely examined
protein and transcript levels following concurrent exposure of
HUVECs to progesterone and LPS (Figs. 4–6). As predicted, the protein
levels for IL-6 were signiﬁcantly reduced in the presence of progester-
one (Fig. 4A). This correlated with a signiﬁcant decrease in transcript
levels as early as 1 h after progesterone treatment (Fig. 4B).
IL-8/CXCL8 showed a similar expression pattern to that of IL-6, but
regulation by progesterone was not as pronounced (Fig. 5A, D).
CXCL10/IP-10 RNA levels were negatively regulated by progesterone
at early time points, yet protein levels were not signiﬁcantly reduced
until 24 h after treatment (Fig. 5B, E). Interestingly, transcript levels
of CXCL1/GRO were signiﬁcantly downregulated by progesterone at
very early time points of 1 and 2 h (Fig. 5F). This correlated with a re-
duction in protein at 4 and 8 h, yet this phenomenon did not extend
to 24 h (Fig. 5C).
Progesterone signiﬁcantly reduced RNA levels of the CCL family
member,MCP-1/CCL2, yet decreased protein levels did not reach signif-
icance (Fig. 6A, C). Alternatively, the CX3C family member, CX3CL1/
fractalkine, although not found to be signiﬁcantly reduced by RNA-seq
analysis, did show signiﬁcant reduction in both RNA and protein ex-
pression at all times of progesterone treatment (Fig. 6B, D).
4. Discussion
Hormones are believed to play an important role in the sexual
dimorphism underlying diseases with immune etiologies (Gilliver,
2010; Hughes, 2012; Martocchia et al., 2011). Clearly interdependence
exists between different hormonal signaling pathways in immune reg-
ulation, yet this complexitymakes it difﬁcult to assess the contributions
of individual steroid hormones, particularly in vivo. Although several
studies have demonstrated the anti-inﬂammatory properties of proges-
terone within the context of its reproductive functions (Challis et al.,
2009; Gilliver, 2010; Jones, 2004; King and Critchley, 2010; Red-Horse
and Drake, 2004; van Mourik et al., 2009), little is understood as to its
direct cellular andmolecular targetswith respect to immune regulation.
As the vascular endothelium is known to mediate leukocyte homing
and selective extravasation, we hypothesized that progesterone
signaling might transcriptionally modulate the activation state of the
endothelium in response to an acute inﬂammatory stimulus. Using un-
biased global expression analysis we demonstrated that progesterone
signaling, via PR, directly suppresses a select group of cytokine and
chemokines expressed by the endothelium. This reduction was seen
both under physiological and pathological activation by LPS, indicatingFig. 4. IL-6 repression by progesterone stimulation. (A) Protein expression (pg/μL) of IL-6 d
nation with progesterone (hatched bars) for the indicated times. Graphs depict an avera
expression. HUVECs were treated with LPS (solid bars) or in combination with progestero
made relative to PR infected HUVECs in the absence of both LPS and progesterone (red hatch
to progesterone. Graphs depict an average of three biological replicates run in triplicate. *pthat endothelial cells are also susceptible to anti-inﬂammatory regula-
tion by progesterone.
Our results indicate that under homeostatic conditions, endothelial
expression of PR is selective to veins and conspicuously absent from ar-
teries. This exquisite speciﬁcity is consistent with the fact that immune
trafﬁcking occurs predominantly in venules and lymphatics (Pober and
Sessa, 2007). Thus, restricted expression allows spatial regulation of PR
function in response to a systemically distributed ligand. Although PR is
not constitutively expressed in the endothelium, its focal and sporadic
expression may be indicative of a tightly regulated and precisely local-
ized function. Although not much is known of the role of PR in the
endothelium, a select group of in vitro studies have shown that PR can
inhibit the expression of the endothelial–leukocyte adhesion molecule,
VCAM-1, and the cytokines IL-8 and MCP-1 (Okada et al., 1998; Otsuki
et al., 2001; Simoncini, 2004), yet no study has assessed global expres-
sion of endothelial genes upon progesterone stimulation.
To examine the contribution of PR in the vascular endothelium at
the molecular level, we employed a cell culture based system using
HUVECs. Using global transcriptome analysis we examined cytokine
production from the endothelium in the presence of LPS. Of 70 cyto-
kines examined, 29 of these displayed altered expression in the pres-
ence of LPS, yet only 15 were considered statistically signiﬁcant. From
these, 5 were signiﬁcantly downregulated by progesterone (IL-8, IL-6,
CCL2, CXCL1 and CXCL2/3) while 4 (IL-6, IL-8, CXCL1, and CXCL2)
were directly bound by PR. These ﬁndings are intriguing as not only
does the endothelium itself preferentially produce a unique subset
of cytokines in response to LPS, but only a small proportion of these
are presumably controlled by PR. Therefore, progesterone may mod-
ulate speciﬁc leukocyte subsets in response to an acute inﬂammatory
event. Indeed, the majority of the direct cytokine/chemokine targets
of progesterone noted in this study were found to be neutrophil/
monocyte attractants (Hamilton et al., 2012; Romano et al., 1997).
Biologically, the local tissue response to withdrawal of progester-
one shows many features characteristic of an inﬂammatory response
(Gilliver, 2010; King and Critchley, 2010; Oertelt-Prigione, 2012).
Following progesterone decline in the circulation that precedes men-
struation, there is a signiﬁcant inﬂux of neutrophils, eosinophils, and
macrophages into the uterus, which are likely critical for focal inﬂam-
matory mediated endometrial repair (Henriet et al., 2012). Analysis
of whole decidual tissue has implicated MCP-1, IL-8, IL-6, MDC,
fractalkine, eotaxin, and MCP-3 following the decline in progesterone
levels that initiate menstruation (Angstwurm et al., 1997; Critchley et
al., 1999; Hamilton et al., 2013; Hannan et al., 2004; Jones, 2004;
Jones et al., 1997; Zhang et al., 2000). Moreover, IL-8 and MCP-1
levels as well as monocyte numbers are increased in human decidua
from women taking the PR inhibitor, mifepristone (Critchley et al.,
1996). Furthermore, the expression of these two cytokines (both inetermined by cytokine array. HUVECs were treated with LPS (solid bars) or in combi-
ge of three biological replicates. *p b 0.01, **p b 0.001. (B) qPCR conﬁrmation of IL-6
ne (hatched bars) for the indicated times. Ct values were normalized to GAPDH and
ed bar). GFP infected cells (ﬁrst three bars) were used as a control and did not respond
b 0.01, **p b 0.001, ***p b 0.0001, and ****p b 0.00001.
Fig. 5. Progesterone regulation of CXC chemokine family members. (A-C) Protein expression (pg/μL) of CXCL8/IL-8 (A) CXCL10/IP-10 (B) and CXCL2/GRO (C) as determined by cy-
tokine array. HUVECs were treated with LPS (solid bars) or in combination with progesterone (hatched bars) for the indicated times. Graphs depict an average of three biological
replicates. *p b 0.01, **p b 0.001, ***p b 0.0001. (D-F) qPCR conﬁrmation of CXCL8/IL-8 (D) CXCL10/IP-10 (E) and CXCL2/GRO (F). HUVECs were treated with LPS (solid bars) or in
combination with progesterone (hatched bars) for the indicated times. Ct values were normalized to GAPDH and made relative to PR infected HUVECs in the absence of both LPS
and progesterone (red dotted bar). GFP infected cells (ﬁrst three bars) were used as a control and did not respond to progesterone. Graphs depict an average of three biological
replicates run in triplicate. ***p b 0.0001, ****p b 0.00001.
41L.M. Goddard et al. / Vascular Pharmacology 59 (2013) 36–43vitro and in vivo) was inhibited by progesterone (Jones et al., 1997;
Kelly et al., 1994; Loudon et al., 2003; Luk et al., 2010).
Similar to menstruation, proinﬂammatory cytokines also play a
central role in the mechanisms of term and inﬂammation/infection-
induced preterm parturition (Hamilton et al., 2013; MacIntyre et al.,
2012; Norman et al., 2007). Cytokines associated with this process
also include MCP-1, IL-8 and IL-6, in addition to RANTES, and
MIP-B1 (Hamilton et al., 2012, 2013; Robertson et al., 2010). As pro-
gesterone is capable of inhibiting the expression of MCP-1, IL-8, and
IL-6 in the endothelium, it is possible that the vasculature plays a
critical role in maintaining an immunosuppressive environment in
the uterus prior to these immune-mediated events. Naturally, other
cell types, including stromal and epithelial cells also play key roles
in immune regulation (Hamilton et al., 2013).
Interestingly, we determined that GRO/CXCL1/2/3 is a direct target
of progesterone in the endothelium, yet a role for GRO has not been
revealed with regard to reproductive immune inﬁltration. Recently,
progesterone has been found to inhibit expression of GRO in ovarian
and endometrial cancer cells as well as dendritic cells (Kavandi et al.,
2012; Zhao et al., 2013). As GRO is a potent chemoattractant for neutro-
phils, more so than IL-8, suppression of GRO by progesterone may play
an even stronger role in the inhibition of neutrophil trafﬁcking.
To conﬁrm that progesterone mediated changes in RNA expres-
sion correlated with differential protein production, we performed
an unbiased bead-based multiplex cytokine array. While all of thecytokines determined to be transcriptionally modulated following
RNA-seq analysis were regulated at the protein level, two additional
cytokines, fractalkine/CX3CL1 and CXCL10/IP-10, were also found to
be downregulated following analysis of the multiplex array. Subse-
quent qPCR analysis conﬁrmed this reduction at the RNA level.
Based on our analysis of the RNA-seq data, CXCL10 did not meet
the criteria as being signiﬁcantly regulated by LPS, and thus was ex-
cluded from further evaluation. In addition, although LPS signiﬁcantly
modulated CX3CL1 expression, it was not signiﬁcantly altered by pro-
gesterone. It is likely that these two cytokines are targets of proges-
terone, but due to the stringent statistical analysis used for our
RNA-seq datasets these cytokines were not found to be signiﬁcant.
5. Conclusion
The results of this study provide detailed insight into the endothe-
lial cell speciﬁc role of progesterone signaling in the regulation of
cytokine production. PR directly suppresses the expression of a small
subset of cytokines both under physiological conditions and following
stimulation by LPS. These results conﬁrm PR as an anti-inﬂammatory
agent in the endothelium, with potential for the negative regulation of
immune cell trafﬁcking into tissues. Understanding the factors and
cell populations that control immune cells will further clarify gender
differences in disease as well as dysregulated immune-mediated repro-
ductive processes such as preterm labor.
Fig. 6. Progesterone regulation of the CC and CX3C family members. (A,B) Protein expression (pg/μL) of CCL2 (A) and CX3CL1/fractalkine (B) as determined by cytokine array.
HUVECs were treated with LPS (solid bars) or in combination with progesterone (hatched bars) for the indicated times. Graphs depict an average of three biological replicates.
(C,D) qPCR conﬁrmation of CCL2 (C) and CX3CL1 (D). HUVECs were treated with LPS (solid bars) or in combination with progesterone (hatched bars) for the indicated times. Ct
values were normalized to GAPDH and made relative to PR infected HUVECs in the absence of both LPS and progesterone (red dotted bar). GFP infected cells (ﬁrst three bars)
were used as a control and did not respond to progesterone. Graphs depict an average of three biological replicates run in triplicate. *p b 0.01, **p b 0.001, ***p b 0.0001,
****p b 0.00001.
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